ESMO GI 2024 Insights: 1L Unresectable HCC - Outcomes by Comorbidities With STRIDE (Durvalumab & Tremelimumab Regimen) in the HIMALAYA Study

145 views
July 5, 2024
Comments 0
Login to view comments. Click here to Login